ORG
Lykos Faces Setback as ICER Concludes Insufficient Evidence for MDMA-Based PTSD Treatment
Lykos Therapeutics, MDMA, PTSD, ICER, Insufficient Evidence, Clinical Trials, FDA Approval
Alumis Secures $250 Million in Downsized Initial Public Offering
Alumis, Immunology Biotech, IPO, Initial Public Offering, Funding, Biotechnology
FDA Rejects Merck-Daiichi Sankyo’s Lung Cancer Drug, Approves New Treatments for COPD and Lymphoma
FDA, Merck, Daiichi Sankyo, NSCLC, COPD, Lymphoma, Patritumab Deruxtecan, Ensifentrine, Epkinly
Novo Nordisk Acquires 2seventy’s Gene Editing Technology and Haemophilia Candidate for $40 Million
Novo Nordisk, 2seventy, gene editing, haemophilia, MegaTAL, in vivo gene editing technology
EuroAPI to Cut 550 Jobs, Divest Facilities in Streamlining Plan to Reduce Reliance on Sanofi
EuroAPI, job cuts, streamlining plan, Sanofi, facility divestiture, restructuring
FDA Rejects Merck-Daiichi’s HER3-Targeted ADC Due to Manufacturing Issues
FDA, Merck, Daiichi Sankyo, HER3-targeted ADC, patritumab deruxtecan, manufacturing concerns, lung cancer treatment
Medicare Patients to Save on 64 Prescription Drugs with Prices Above Inflation Rate
Medicare, Prescription Drugs, Inflation Reduction Act, Price Rebates, Healthcare Costs
EU Calls for Cooperation and Increased Manufacturing to Overcome GLP-1 Shortage
GLP-1 receptor agonists, EU, shortages, diabetes, weight management, manufacturing, cooperation, regulatory actions
US Supreme Court Rejects Purdue’s Multibillion-Dollar Opioid Pact
US Supreme Court, Purdue Pharma, Opioid Settlement, Sackler Family, Bankruptcy, Opioid Crisis
Arc Institute Unveils Revolutionary Bridge Editing Technology for Programmable Genome Design
Bridge editing, genome design, programmable gene editor, DNA strands, Arc Institute, CRISPR, RNA-guided systems, genetic engineering